Sudarshan Jain takes charge as IGBA Chairperson for 2021
Sudarshan Jain takes charge as IGBA Chairperson for 2021
12 January 2021 | News Jain is a well-known veteran in the pharmaceutical industry and brings with him decades of strong leadership and drug policy experience
Source: linkedin.com
IGBA, the International Generic and Biosimilar Medicines Association, representing global manufacturers of generic and biosimilar medicines, has announced that Sudarshan Jain, Secretary General of the Indian Pharmaceutical Alliance (IPA), is taking over the position of IGBA Chair for 2021 from Hanan Sboul, Secretary General of the Jordanian Association of Pharmaceutical Manufacturers.
The incoming IGBA Chair Sudarshan Jain is a well-known veteran in the pharmaceutical industry and brings with him decades of strong leadership and drug policy experience.
Sudarshan Jain takes charge as IGBA Chairperson for 2021
Sudarshan Jain takes charge as IGBA Chairperson for 2021
12 January 2021 | News Jain is a well-known veteran in the pharmaceutical industry and brings with him decades of strong leadership and drug policy experience
Source: linkedin.com
IGBA, the International Generic and Biosimilar Medicines Association, representing global manufacturers of generic and biosimilar medicines, has announced that Sudarshan Jain, Secretary General of the Indian Pharmaceutical Alliance (IPA), is taking over the position of IGBA Chair for 2021 from Hanan Sboul, Secretary General of the Jordanian Association of Pharmaceutical Manufacturers.
The incoming IGBA Chair Sudarshan Jain is a well-known veteran in the pharmaceutical industry and brings with him decades of strong leadership and drug policy experience.
Filgrastim Biosimilars Global Market Report 2020-30: COVID-19 Growth and Change
New York, Dec. 18, 2020 (GLOBE NEWSWIRE) Reportlinker.com announces the release of the report Filgrastim Biosimilars Global Market Report 2020-30: COVID-19 Growth and Change - https://www.reportlinker.com/p05998720/?utm source=GNW
, Biocon and Aryogen Biopharma.
The global filgrastim biosimilars market is expected to decline from $511.15 million in 2019 to $445.04 million in 2020 at a compound annual growth rate (CAGR) of -12.93%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $751.96 billion in 2023 at a CAGR of 19.11%.